MicroVention, Inc. announced today the results of the HELPS trial, which compared the performance of its HydroCoil aneurysm treatment to that of traditional platinum coils. The study found that treatment with this new hydrogel-based system resulted in lower rates of recurrence and retreatment. The HydroCoil system utilizes an expandable hydrogel which swells up when it comes in contact with blood, thereby resulting in better filling of an aneurysm than treatment with a bare coil.
Some results from the study:
HydroCoil had more stable angiographic results with a significant decrease in major remnant/recurrence rates. The primary endpoint of reduction of major aneurysm remnant and recurrence, while neutral, showed a strong trend favoring HydroCoil. There was a very low overall retreatment rate of 3.5% (2.9% HydroCoil vs. 3.6% Bare Platinum). The effect of HydroCoil on major recurrence was superior in ruptured aneurysms and where increased filling by HydroCoil was achieved. There was a reduction of 20% in HydroCoil length used as compared to bare platinum. Because of HydroCoil’s ability to expand into the aneurysm, there was higher packing density: 68.3% for HydroCoil and 24.9% for bare platinum.
Press release: Final Data in International Trial Supports Safety and Effectiveness of MicroVention-Terumo’s HydroCoil® Embolic System for Treatment of Cerebral Aneurysms…
Product page: HydroCoil…
Flashbacks: Medgadget hydrogel archives…